IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
6
Bullish
5
Bearish
19
Neutral
6
Bullish
21
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Bilcare Ltd (BI) is currently trading at 79.06 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Bilcare Limited is a research-led specialty pharmaceutical packaging company that manufactures barrier films, cold-formed blisters, aluminum foils and provides clinical research and packaging services, using dedicated facilities such as its Rajgurunagar plant in Pune and a network of global depots to serve pharmaceutical companies and CROs worldwide. On a consolidated basis Bilcare reported total income of Rs 763.54 crores for the year ended March 31, 2026, down from Rs 806.51 crores the prior year; the company reported a quarterly profit after tax of Rs 7.85 crores for Q4 but a consolidated full-year loss after tax of Rs 17.29 crores, highlighting fiscal volatility. Bilcare executed a material strategic transaction in March 2023 when it transferred its Pharma Packaging Division to Caprihans India Limited for Rs 213 crores, and in FY2025 the company prioritized primary and secondary packaging, enhanced blinding techniques, cold storage and expanded global depot partnerships to support regulatory audits and clinical supply chains. The company emphasizes proprietary packaging innovations — including ‘Bilcare Armour’ and specialized triplex and duplex film laminates — and operates a distinctive Rajgurunagar facility described as one of its kind in Asia, giving Bilcare a technical edge in moisture- and oxygen-sensitive pharmaceutical packaging solutions.
Over the past 52 weeks, Bilcare Ltd has traded between a low of ₹50.00 and a high of ₹114.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Bilcare Ltd has a market capitalization of approximately 177.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Bilcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 177.32 Cr, Bilcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Bilcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Bilcare Ltd is 16.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bilcare reported consolidated net profit of Rs 15.14 crore for the half year ended 30 September 2026. It had reported a consolidated net loss of Rs 19.25 crore in the corresponding half year ended 30 September 2025. Profit attributable to equity owners was Rs 15.93 crore in the latest half.
Bilcare’s auditor said operating losses in past years created material uncertainty that may cast significant doubt on Bilcare’s ability to continue as a going concern. The auditor said Bilcare’s continuity depends on strategic-plan execution, projected cash flows and future GCS-business prospects.
Bilcare reported FY26 total revenue of ₹7,335.37 million for the year ended 31 March 2026. This was 6.92% lower than the ₹7,880.36 million reported in FY25.
Bilcare Limited is a research-led specialty pharmaceutical packaging company that manufactures barrier films, cold-formed blisters, aluminum foils and provides clinical research and packaging services, using dedicated facilities such as its Rajgurunagar plant in Pune and a network of global depots to serve pharmaceutical companies and CROs worldwide.
On a consolidated basis Bilcare reported total income of Rs 763.54 crores for the year ended March 31, 2026, down from Rs 806.51 crores the prior year; the company reported a quarterly profit after tax of Rs 7.85 crores for Q4 but a consolidated full-year loss after tax of Rs 17.29 crores, highlighting fiscal volatility.
Bilcare executed a material strategic transaction in March 2023 when it transferred its Pharma Packaging Division to Caprihans India Limited for Rs 213 crores, and in FY2025 the company prioritized primary and secondary packaging, enhanced blinding techniques, cold storage and expanded global depot partnerships to support regulatory audits and clinical supply chains.
The company emphasizes proprietary packaging innovations — including ‘Bilcare Armour’ and specialized triplex and duplex film laminates — and operates a distinctive Rajgurunagar facility described as one of its kind in Asia, giving Bilcare a technical edge in moisture- and oxygen-sensitive pharmaceutical packaging solutions.
Healthcare Services
Healthcare Research, Analytics & Technology
186 Cr
Low Risk
16.8
59.5
0.1
1.0
114.55
50.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
12.92 | 191 Cr | 32.39 | 6.17 | 0.00 | 13.73 | 15.37 | 35.38 | ||
67.02 | 191 Cr | -74.83 | 2.90 | 0.00 | 5.50 | 6.70 | 3.92 | ||
88.71 | 178 Cr | 22.24 | 2.32 | 0.00 | 1.60 | 4.43 | 4.80 | ||
75.31 | 177 Cr | 16.00 | 0.99 | 0.00 | 20.48 | 11.55 | 2.06 | ||
32.67 | 112 Cr | 24.10 | 1.87 | 0.00 | 7.75 | 8.97 | 6.14 | ||
17.00 | 25 Cr | 19.47 | 0.64 | 0.00 | 3.30 | 5.52 | 2.51 | ||
19.85 | 14 Cr | 128.36 | 0.67 | 0.00 | 0.51 | 1.31 | 0.17 | ||
| Median: 7 Co. | — | 32.67 | 177 Cr | 22.24 | 1.87 | 0.00 | 5.50 | 6.70 | 3.92 |
